Meeting
2016 Genitourinary Cancers Symposium
Treatment patterns after abiraterone acetate in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Post hoc analysis of COU-AA-302.
Authors
Thomas W. Flaig
University of Colorado Cancer Center, Aurora, CO
Thomas W. Flaig , Matthew R. Smith , Fred Saad , Dana E. Rathkopf , Peter F.A. Mulders , Eric Jay Small , Neal D. Shore , Karim Fizazi , Peter De Porre , Thian Kheoh , Jinhui Li , Mary Beth Todd , Thomas W. Griffin , Charles J. Ryan , Johann S. De Bono
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT00887198
Citation
J Clin Oncol 34, 2016 (suppl 2S; abstr 168)
DOI
10.1200/jco.2016.34.2_suppl.168
Abstract #
168
Poster Bd #
G3
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Quality Care Symposium
Real-world treatment patterns among men with metastatic castration-resistant prostate cancer (mCRPC) in the U.S. Medicare population.
First Author: Stephen J. Freedland
Poster
2022 ASCO Genitourinary Cancers Symposium
Real-world treatment patterns among patients with metastatic castration-resistant prostate cancer (mCRPC) in the US.
First Author: Elisabetta Malangone-Monaco
Poster
2019 Genitourinary Cancers Symposium
Treatment patterns and outcomes for metastatic castration-resistant prostate cancer (mCRPC) in a real-world setting: A retrospective study of greater than 2500 patients.
First Author: Celestia S. Higano
Poster
2018 Genitourinary Cancers Symposium
Treatment patterns for metastatic hormone-sensitive prostate cancer (mHSPC) progressing after up-front docetaxel in combination with androgen deprivation therapy (D-ADT).
First Author: Pedro C. Barata